**Amendments to the claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein

- $R_1$ and $R_4$ are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, $C_{1-2}$alkyl, $C_1$alkoxy, halo$C_{1-2}$alkyl, halo$C_1$alkoxy, hydroxy, cyano and nitro;
- $R_2$ and $R_3$ are independently selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, nitro, $C_{1-4}$alkyl, halo$C_{1-4}$alkyl, $C_{3-6}$cycloalkyl, $C_{1-4}$alkoxy, halo$C_{1-4}$alkoxy, $C_{1-4}$alkoxy$C_{1-4}$alkoxy, $C_{1-4}$alkylthio, $C_{1-4}$alkoxy$C_{1-4}$alkyl, $C_{3-6}$cycloalkyl$C_{1-4}$alkoxy, $C_{1-4}$alkanoyl, $C_{1-4}$alkoxycarbonyl, $C_{1-4}$alkoxycarbonyl$C_{1-4}$alkyl, $C_{1-4}$alkylsulfonyl, $C_{1-4}$alkylsulfonyloxy, halo$C_{1-4}$alkylsulfonyl, halo$C_{1-4}$alkylsulfonyloxy, $C_{1-4}$alkylsulfonyl$C_{1-4}$alkyl, $C_{1-4}$alkylsulfonamido, $C_{1-4}$alkylsulfonamido$C_{1-4}$alkyl, heterocyclyl, aryl, aryl$C_{1-4}$alkoxy, aryloxy, arylthio, arylmethyl, aroyl, aryloxymethyl, arylsulfonyl, aryl-NR'- (wherein R' is hydrogen or $C_{1-4}$alkyl), arylsulfonyloxy, arylsulfonyl$C_{1-4}$alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamido$C_{1-4}$alkyl, arylcarboxamido$C_{1-4}$alkyl, aroyl$C_{1-4}$alkyl, aryl$C_{1-4}$alkanoyl, a group $R_{11}CON(R_{12})(CH_2)_r$, $R_{11}R_{12}NCO(CH_2)r$ or $R_{11}R_{12}NSO_2(CH_2)_r$ (in which r is 0, 1, 2, 3 or 4, and each of $R_{11}$ and $R_{12}$ is independently hydrogen or $C_{1-4}$alkyl, or in the groups $R_{11}CON(R_{12})(CH_2)_r$, $R_{11}R_{12}NCO(CH_2)_r$ and $R_{11}R_{12}NSO_2(CH_2)_r$, $R_{11}CONR_{12}$ or $R_{11}R_{12}N$ together form a 4-, 5-, 6- or 7-membered azacyclic group optionally containing one additional O, N or S atom in the azacycle and having 3-8 carbon atoms (including the carbon atoms contained in any optional substituent(s) of the azacycle)); wherein in any group containing an aryl moiety, the aryl may be substituted by one, two or three groups selected from the group consisting of halogen, hydroxy, cyano, nitro, amino, $C_{1-4}$alkyl, halo$C_{1-4}$alkyl, $C_{1-4}$alkoxy, halo$C_{1-4}$alkoxy, $C_{1-4}$alkylenedioxy, $C_{1-4}$alkanoyl, $C_{1-4}$alkylsulfonyl, halo$C_{1-4}$alkylsulfonyl, $C_{1-4}$alkylamino, $C_{1-4}$

$_4$dialkylamino, $R_{13}R_{14}NCO$ (in which $R_{13}$ and $R_{14}$ are independently hydrogen or $C_{1-4}$alkyl, or $R_{13}R_{14}N$ together form a 4-, 5-, 6- or 7-membered azacyclic group optionally containing one additional O, N or S atom in the azacycle and having 3-8 carbon atoms (including the carbon atoms contained in any optional substituent(s) of the azacycle));

- A and B are independently N or CH;
- $R_5$, $R_6$, $R_7$, $R_8$ and $R_9$ are independently hydrogen or $C_{1-4}$alkyl;
- $R_{10}$ is a group of the formula (a) or (b):

(a) (b)

wherein:

- Z is $C_{1-4}$alkyl, halo$C_{1-4}$alkyl, $C_{3-6}$cycloalkyl, phenyl, heterocyclyl, a 5- or 6-membered heteroaromatic ring or a 8- to 11-membered bicyclic group, any of which is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, hydroxy, oxo, cyano, nitro, $C_{1-4}$alkyl, $C_{1-4}$alkoxy, halo$C_{1-4}$alkyl, halo$C_{1-4}$alkoxy, $C_{1-4}$alkylenedioxy, $C_{1-4}$alkanoyl, $C_{1-4}$alkylsulfonyl, $C_{1-4}$alkylsulfonyloxy, halo$C_{1-4}$alkylsulfonyl, halo$C_{1-4}$alkylsulfonyloxy, $C_{1-4}$alkylsulfinyl, $C_{1-4}$alkylthio, $R_{17}SO_2N(R_{18})$-, $R_{17}R_{18}NSO_2$-, $R_{17}R_{18}N$-, $R_{17}R_{18}NCO$-, $R_{17}CONR_{18}$- and a 5- or 6-membered heteroaromatic ring which is optionally substituted by one or two $C_{1-2}$alkyl, halo$C_{1-2}$alkyl or $R_{17}R_{18}N$-(wherein $R_{17}$ and $R_{18}$ are independently hydrogen or $C_{1-4}$alkyl, or $R_{17}$ and $R_{18}$ together form $C_{3-6}$alkylene); and wherein substituents positioned *ortho* to one another may be linked to form a 5- or 6- membered ring; and
- $R_{15}$ and $R_{16}$ are independently hydrogen or $C_{1-4}$alkyl and t is 1, 2, 3 or 4, or -$(CR_{15}R_{16})$t- forms a $C_{3-6}$cycloalkylene linker.

2. (Previously Presented) A compound as claimed in claim 1, wherein $R_3$ is hydrogen.

3. (Previously Presented) A compound as claimed in claim 1 or claim 2, wherein $R_2$ is $C_{1-4}$alkyl, halo$C_{1-4}$alkyl, halogen, $C_{1-4}$alkylsulfonyl (e.g. methylsulfonyl or ethylsulfonyl), halo$C_{1-4}$alkylsulfonyl (e.g. trifluoromethylsulfonyl), $C_{1-4}$alkylsulfonyloxy (e.g. methylsulfonyloxy), halo$C_{1-4}$alkylsulfonyloxy (e.g. trifluoromethylsulfonyloxy), $R_{11}R_{12}NSO_2$ (where each of $R_{11}$ and $R_{12}$ is independently hydrogen or $C_{1-4}$alkyl or $R_{11}R_{12}N$ together form a 4-, 5-, 6- or 7-membered azacyclic group optionally containing one additional O, N or S atom in the azacycle and having 3-8 carbon atoms, e.g. a piperidin-1-ylsulfonyl, pyrrolidin-1-ylsulfonyl or 1,4-

morpholin-4-ylsulfonyl), a 5- or 6-membered heteroaromatic or a heterocyclyl, each of which is optionally substituted by one or two substituents selected from: halogen, cyano, $C_{1-2}$alkyl (e.g. methyl or trifluoromethyl), $C_{1-2}$alkoxy (e.g. methoxy), $C_{1-2}$alkylenedioxy (e.g. methylenedioxy), $C_{1-3}$alkanoyl (e.g. acetyl), $C_2$alkanoylamino (e.g.acetylamino), halo$C_1$alkylsulfonyl (e.g. trifluoromethylsulfonyl) and methylsulfonyl.

4. (Previously Presented) A compound as claimed in claim 3, wherein $R_2$ is bromo, cyano, hydroxy, chloro, methoxy, tert-butyl, methylsulfonyl, ethylsulfonyl, N,N-dimethylaminosulfonyl, pyrrolidin-1-ylsulfonyl, 1,4-morpholin-4-ylsulfonyl, methylsulfonyloxy, pyrazolyl (eg pyrazol-5-yl), 1,3-dimethyl-pyrazol-5-yl, pyrazin-2-yl, 5-methyl-oxazol-2-yl or 5-methyl-isoxazol-3-yl.

5. (Currently Amended) A compound as claimed in ~~any of claims 1-4~~ claim 1, wherein both $R_1$ and $R_4$ are hydrogen.

6. (Currently Amended) A compound as claimed in ~~any of claims 1-5~~ claim 1, wherein A and B are both nitrogen.

7. (Currently Amended) A compound as claimed in ~~any of claims 1-6~~ claim 1, wherein $R_5$, $R_6$, $R_7$ and $R_8$ are all hydrogen.

8. (Currently Amended) A compound as claimed in ~~any of claims 1-7~~ claim 1, wherein $R_9$ is methyl.

9. (Currently Amended) A compound as claimed in ~~any of claims 1-8~~ claim 1, wherein $R_{10}$ is a group of formula (a).

10. (Previously Presented) A compound as claimed in claim 9, wherein in formula (a), Z is phenyl, fluorophenyl, or quinolinyl, each of which is unsubstituted or substituted by one or more substituents selected from: halogen, or cyano, $C_{1-2}$alkyl (e.g. methyl), halo$C_{1-2}$alkyl (e.g. trifluoromethyl), $C_{1-2}$alkoxy (e.g. methoxy), halo$C_{1-4}$alkoxy (e.g. trifluoromethoxy), $C_{1-2}$alkylenedioxy (e.g. methylenedioxy), $C_{2-3}$alkanoyl (e.g. acetyl), $C_2$alkanoylamino (e.g.acetylamino), methylsulfonyl, halo$C_1$alkylsulfonyl (e.g. trifluoromethylsulfonyl), $C_1$alkylsulfonyloxy (e.g. methylsulfonyloxy), $C_1$alkylaminosulfonyl (e.g. methylaminosulfonyl), $C_1$alkylsulfonylamino (e.g. methylsulfonylamino) and $C_1$alkylaminocarbonyl (e.g. methylaminocarbonyl).

11. (Previously Presented) A compound as claimed in claim 1 having a formula (IA) or a pharmaceutically acceptable salt thereof:



(IA)

wherein:

- A, B and $R_9$ are as defined in claim 1;
- X is a 5- or 6-membered heteroaromatic ring optionally substituted by 1, 2 or 3 substituents selected from the group consisting of: halogen, cyano, $C_{1-2}$alkyl, fluoro$C_{1-2}$alkyl, $C_{1-2}$alkoxy, $C_{1-3}$alkanoyl, $C_2$alkanoylamino, fluoro$C_1$alkylsulfonyl and methylsulfonyl; and
- Y is phenyl, heterocyclyl, a 5- or 6-membered heteroaromatic ring or a 8- to 11-membered bicyclic group, any of which is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, $C_{1-2}$alkyl, halo$C_{1-2}$alkyl, $C_{1-2}$alkoxy, halo$C_{1-2}$alkoxy, $C_{1-2}$alkylenedioxy, $C_{2-3}$alkanoyl, $C_2$alkanoylamino, methylsulfonyl, halo$C_1$alkylsulfonyl, methylsulfonyloxy, methylaminosulfonyl, methylsulfonylamino and methylaminocarbonyl.

12. (Previously Presented) A compound as claimed in claim 1 having a formula (IB) or a pharmaceutically acceptable salt thereof:



(IB)

wherein

- X is isoxazolyl or pyrazolyl ring optionally substituted by 1, 2 or 3 substituents selected from the group consisting of: halogen, cyano, $C_{1-2}$alkyl, fluoro$C_{1-2}$alkyl, $C_{1-2}$alkoxy, $C_{1-3}$alkanoyl, $C_2$alkanoylamino, fluoro$C_1$alkylsulfonyl and methylsulfonyl; and
- Y is phenyl, heterocyclyl, a 5- or 6-membered heteroaromatic ring or a 8- to 11-membered bicyclic group, any of which is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, $C_{1-2}$alkyl, halo$C_{1-2}$alkyl, $C_{1-2}$alkoxy, halo$C_{1-2}$alkoxy, $C_{1-2}$alkylenedioxy, $C_{2-3}$alkanoyl, $C_2$alkanoylamino, methylsulfonyl, halo$C_1$alkylsulfonyl, methylsulfonyloxy, methylaminosulfonyl, methylsulfonylamino and methylaminocarbonyl.

13. (Previously Presented) A compound as claimed in claim 1, which is:

7-(5-Methyl-3-isoxazolyl)-3-(2-{[4-methyl-1,3-oxazol-5yl)-4H-1,2,4-triazol-3-yl]thio}ethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine

- 7-(5-Methyl-3-isoxazolyl)-3-(2-{[4-methyl-5-(tetrahydro-2H-pyran-4-yl)-4H-1,2,4-triazol-3-yl]thio}ethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine
- 7-(5-Methyl-3-isoxazolyl)-3-(2-{[4-methyl-5-(2-methyl-5-quinolinyl)-4H-1,2,4-triazol-3-yl]thio}ethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine
- 7-(5-Methyl-3-isoxazolyl)-3-(2-{[4-methyl-5-(2-methyl-6-quinolinyl)-4H-1,2,4-triazol-3-yl]thio}ethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine
- 7-(1,3-Dimethyl-1*H*-pyrazol-5-yl)-3-(2-{[4-methyl-5-(2-methyl-5-quinolinyl)-4*H*-1,2,4-triazol-3-yl]thio}ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine
- 7-(1,3-Dimethyl-1*H*-pyrazol-5-yl)-3-(2-{[4-methyl-5-(5-methyl-2-pyrazinyl)-4*H*-1,2,4-triazol-3-yl]thio}ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine
- 3-(2-{[5-(3,4-Difluorophenyl)-4-methyl-4*H*-1,2,4-triazol-3-yl]thio}ethyl)-7-(1,3-dimethyl-1*H*-pyrazol-5-yl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine
- 7-(5-Methyl-3-isoxazolyl)-3-(2-{[4-methyl-5-(2-methyl-3-pyridinyl)-4*H*-1,2,4-triazol-3-yl]thio}ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine formate
- 7-(5-Methyl-3-isoxazolyl)-3-(2-{[4-methyl-5-(4-pyridazinyl)-4*H*-1,2,4-triazol-3-yl]thio}ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine formate
- 7-(5-Methyl-3-isoxazolyl)-3-[2-({4-methyl-5-[2-methyl-6-(trifluoromethyl)-3-pyridinyl]-4*H*-1,2,4-triazol-3-yl}thio)ethyl]-2,3,4,5-tetrahydro-1*H*-3-benzazepine formate
- 3-(2-{[5-(1,5-Dimethyl-1*H*-pyrazol-4-yl)-4-methyl-4*H*-1,2,4-triazol-3-yl]thio}ethyl)-7-(5-methyl-3-isoxazolyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine formate
- 3-(2-{[5-(5-Chloro-1-methyl-1*H*-pyrazol-4-yl)-4-methyl-4*H*-1,2,4-triazol-3-yl]thio}ethyl)-7-(5-methyl-3-isoxazolyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine formate
- 7-(5-Methyl-3-isoxazolyl)-3-[2-({4-methyl-5-[4-(trifluoromethyl)phenyl]-4*H*-1,2,4-triazol-3-yl}thio)ethyl]-2,3,4,5-tetrahydro-1*H*-3-benzazepine formate
- 3-(2-{[5-(3,4-Difluorophenyl)-4-methyl-4*H*-1,2,4-triazol-3-yl]thio}ethyl)-7-(5-methyl-3-isoxazolyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine formate
- 7-(5-Methyl-3-isoxazolyl)-3-(2-{[4-methyl-5-(5-methyl-2-pyrazinyl)-4*H*-1,2,4-triazol-3-yl]thio}ethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine formate
- 3-(2-{[1-(1-Methylethyl)-5-(methylsulfonyl)-1*H*-benzimidazol-2-yl]thio}ethyl)-7-(5-methyl-3-isoxazolyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine formate

or a pharmaceutically acceptable salt thereof.

14. (Previously Presented) A process for preparing a compound as defined in claim 1, which process comprises:

(a) reacting a compound of formula (II):



(II)

wherein $R_1$ to $R_8$ are as defined for formula (I) and L is a leaving group; with a compound of formula (III):



(III)

wherein A, B, $R_9$ and $R_{10}$ are as defined for formula (I); or



(IV)

(b) for a compound of formula (I) wherein $R_2$ is aryl, reacting a compound of formula (IV):

wherein $R_1$, $R_3$ to $R_{10}$, A and B are as defined for formula (I) and W is halogen or a trifluoromethylsulfonyloxy group, or W is a group M selected from a boron derivative (e.g. a boronic acid function $B(OH)_2$) or a metal function such as trialkylstannyl (e.g. $SnBu_3$), zinc halide or magnesium halide; with a compound aryl-$W^1$, wherein aryl is as defined for formula (I), $W^1$ is halogen or a trifluoromethylsulfonyloxy group when W is a group M or $W^1$ is a group M as defined above when W is halogen or a trifluoromethylsulfonyloxy group; or

(c) for a compound of formula (I) wherein $R_2$ is aryloxy or arylthio, reacting a compound of formula (V):



(V)

wherein G is oxygen or sulfur, and $R_1$, $R_3$ to $R_{10}$, A and B are as defined for formula (I); with a reagent serving to introduce the aryl group;

and optionally thereafter for any of the steps (a), (b) or (c):

- removing any protecting group(s); and/or
- forming a salt; and/or
- converting one compound of formula (I) to a different compound of formula (I).

15. (Currently Amended) A method of treating a condition for which modulation of dopamine $D_3$ receptors is beneficial, which comprises administering to a mammal (e.g. human) in need thereof an effective amount of a compound of a compound of ~~any of claims 1-13~~ claim 1.

16. (Previously Presented) A method as claimed in claim 15, wherein the condition is substance abuse and/or drug dependency.

17. (Previously Presented) A method as claimed in claim 16, wherein the condition is craving for abused substance and/or relapse to drug seeking and drug taking behaviour.

Claims 18-20. (Canceled)

21. (Currently Amended) A compound as claimed in ~~any of claims 1-13~~ claim 1 for use in therapy.

22. (Currently Amended) A compound as claimed in ~~any of claims 1-13~~ claim 1 for use in the treatment of a condition in a mammal for which modulation of dopamine D3 receptors is beneficial.

23. (Currently Amended) A compound as claimed in ~~any of claims 1-13~~ claim 1 for use in the treatment of substance abuse and/or drug dependency.

Claim 24. (Canceled)

25. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in ~~any of claims 1-13~~ claim 1 and a pharmaceutically acceptable carrier.